Human‑First Science. NAMs‑Driven Innovation--From Bench to IND
Combining trusted methods with NAMs to make drug development regulatory‑ready and predictive
SPECCRO: Your Specialty Research Organization
Preclinical Efficacy & Safety Assessment Needs a New Approach
- 90% of new drug candidates that enter clinical trials fail due to lack of efficacy and non monitorable toxicity.
- In 2024 alone, seven clinical programs failed for safety or efficacy after promising preclinical results
- Unbearable costs of drug development.
- FDA, EMA and UK's recent announcement plans to phase out animal testing requirements.
- The FDA is committed to reducing and replacing animal testing by encouraging NAM‑based nonclinical studies and sponsor engagement to optimize their use across diverse contexts, supporting drug safety and efficacy
SPECCRO: Your End-to-End Drug Development Partner
- SPECCRO is the architect of preclinical drug development strategy, guiding sponsors through every step of the process as a virtual extension of your internal team
- Superior efficacy & safety profile, reduced attrition, reduced animal use will materially improve the cost and speed of drug development
- Industry‑leading veterans with advanced degrees and specialty certifications bring decades of experience building laboratories, leading regulatory interactions on novel tools, and solving complex pathology issues. Supported by therapeutic expertise, our Data Hub, and chip reproducibility testing lab, we provide curated capabilities beyond what larger organizations sustain or startups access.
SPECCRO Advantage
Our Human‑Centric NAMs Platform integrates traditional paradigms with NAMs, in‑vitro systems, and computational models to deliver smarter, human‑focused drug development aligned with 3R principles. With decades of experience in laboratory building, regulatory interactions, and complex programmatic challenges, our veteran team offers curated services and capabilities supported by therapeutic expertise. We scale seamlessly to program needs, providing direct communication, personalized collaboration, and Therapeutic Execution Hub expertise that accelerates decisions and streamlines workflows. Acting as an extension of your research team, we define the right endpoints, co‑develop fit‑for‑purpose solutions, and drive IND‑enabling success with precision and partnership.
SPECCRO TEAM
Shashi Ramaiah, Founder & CEO
Todd Bucciarelli, Advisory Board Member
Todd Bucciarelli, Advisory Board Member
Todd Bucciarelli, Advisory Board Member
Todd Bucciarelli, Advisory Board Member
Todd Bucciarelli, Advisory Board Member
Brian Berridge, Advisory Board Member
Todd Bucciarelli, Advisory Board Member
Brian Berridge, Advisory Board Member
Devang Parikh, Advisory Board Member
Blanca Rodriguez, Advisory Board Member
Brian Berridge, Advisory Board Member
Armin Wolf, Advisory Board Member
Blanca Rodriguez, Advisory Board Member
Blanca Rodriguez, Advisory Board Member
Blanca Rodriguez, Advisory Board Member
Blanca Rodriguez, Advisory Board Member
Blanca Rodriguez, Advisory Board Member
John Burkhardt, Advisory Board Member
Chandra Williams, In Vivo Operations & Compliance
John Burkhardt, Advisory Board Member
Sandeep Menon, Advisory Board Member
Chandra Williams, In Vivo Operations & Compliance
John Burkhardt, Advisory Board Member
Chandra Williams, In Vivo Operations & Compliance
Chandra Williams, In Vivo Operations & Compliance
Chandra Williams, In Vivo Operations & Compliance